Trials / Terminated
TerminatedNCT05238025
MVA-BN-RSV Vaccine Trial
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN® -RSV Vaccine in Adults ≥60 Years of Age
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 20,419 (actual)
- Sponsor
- Bavarian Nordic · Industry
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Accepted
Summary
Phase 3 randomized, double blind study comparing recombinant MVA-BN-RSV vaccine vs placebo for efficacy and safety in adults \>=60 years of age
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MVA-BN-RSV vaccine | One injection, suspension for injection, intramuscular use, 0.5mL MVA-BN-RSV virus with a titer of at least 3 x 10E8 infectious units (Inf.U)/0.5mL in a Tris buffer at pH 7.7. |
| BIOLOGICAL | Tris Buffered Saline (TBS) | One injection, solution for injection, intramuscular use, 0.5mL TBS, pH 7.7. |
Timeline
- Start date
- 2022-04-19
- Primary completion
- 2023-06-29
- Completion
- 2023-09-01
- First posted
- 2022-02-14
- Last updated
- 2024-10-31
- Results posted
- 2024-10-31
Locations
120 sites across 2 countries: United States, Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05238025. Inclusion in this directory is not an endorsement.